Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) have announced plans to begin a Phase III cardiovascular outcomes trial (CVOT) to assess the potential of zilebesiran, an RNAi therapeutic, in lowering the occurrence of major adverse cardiovascular events among individuals with uncontrolled hypertension. This decision follows the outcomes of the comprehensive KARDIA Phase II program, which consisted of KARDIA 1, KARDIA 2, and the recent KARDIA-3 study. These trials focused on examining the effectiveness and safety of zilebesiran in patients dealing with uncontrolled hypertension and carrying a high cardiovascular (CV) risk while being treated with two to four standard antihypertensives. Specifically, KARDIA-3 aimed to define the patient cohort for the upcoming Phase III CV outcomes trial.